VIRI Stock Overview
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Virios Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.43 |
| 52 Week High | US$2.42 |
| 52 Week Low | US$0.28 |
| Beta | 1.88 |
| 1 Month Change | -5.77% |
| 3 Month Change | 11.34% |
| 1 Year Change | -55.57% |
| 3 Year Change | -92.26% |
| 5 Year Change | n/a |
| Change since IPO | -97.42% |
Recent News & Updates
Recent updates
Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?
Aug 24
Can Virios Therapeutics (NASDAQ:VIRI) Afford To Invest In Growth?
May 11Virios Therapeutics slides 11% postmarket on proposed stock offering
Sep 19Virios Therapeutics GAAP EPS of -$0.44 beats by $0.07
Aug 11Here's Why We're Watching Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation
Jun 25Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?
Mar 09Will Virios Therapeutics (NASDAQ:VIRI) Spend Its Cash Wisely?
Nov 02Here's Why We're Not Too Worried About Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation
Jul 19Virios Therapeutics shares rise after dosing first patient in mid-stage fibromyalgia study
Jun 04Virios Therapeutics (NASDAQ:VIRI) Is In A Good Position To Deliver On Growth Plans
Mar 31Virios Therapeutics gains 10% on research deal in irritable bowel syndrome
Feb 01Virios Therapeutics prices IPO at $10
Dec 17Shareholder Returns
| VIRI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.6% | -2.5% | -3.2% |
| 1Y | -55.6% | -3.7% | 19.3% |
Return vs Industry: VIRI underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: VIRI underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| VIRI volatility | |
|---|---|
| VIRI Average Weekly Movement | 18.7% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VIRI's share price has been volatile over the past 3 months.
Volatility Over Time: VIRI's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 4 | Greg Duncan | www.virios.com |
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company’s lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID.
Virios Therapeutics, Inc. Fundamentals Summary
| VIRI fundamental statistics | |
|---|---|
| Market cap | US$8.20m |
| Earnings (TTM) | -US$5.30m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.6x
P/E RatioIs VIRI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIRI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$5.30m |
| Earnings | -US$5.30m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.28 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did VIRI perform over the long term?
See historical performance and comparison